Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase 3, Open-label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 <50%

Trial Profile

A Randomized, Phase 3, Open-label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 <50%

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2018

At a glance

  • Drugs Cemiplimab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Ipilimumab; Paclitaxel; Pemetrexed
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms EMPOWER-lung 3
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 26 Sep 2018 Trial design of the study presented at the 19th World Conference on Lung Cancer.
    • 09 Jun 2018 Planned End Date changed from 7 May 2022 to 18 Jul 2022.
    • 09 Jun 2018 Planned primary completion date changed from 7 May 2022 to 18 Jul 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top